dc.contributor.author | Spain, L | |
dc.contributor.author | Schmid, T | |
dc.contributor.author | Gore, M | |
dc.contributor.author | Larkin, J | |
dc.date.accessioned | 2017-04-10T16:17:05Z | |
dc.date.issued | 2017-04-01 | |
dc.identifier.citation | European journal of cancer (Oxford, England : 1990), 2017, 75 pp. 243 - 244 | |
dc.identifier.issn | 0959-8049 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/575 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.doi | 10.1016/j.ejca.2016.12.040 | |
dc.format | Print-Electronic | |
dc.format.extent | 243 - 244 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCI LTD | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Melanoma | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Ipilimumab | |
dc.subject | Nivolumab | |
dc.title | Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-12-06 | |
rioxxterms.versionofrecord | 10.1016/j.ejca.2016.12.040 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of cancer (Oxford, England : 1990) | |
pubs.notes | 12 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 75 | |
pubs.embargo.terms | 12 months | |
icr.researchteam | Melanoma and Kidney Cancer | |
dc.contributor.icrauthor | Spain, Lavinia | |